Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBlue Shield CA CMA Pregnancy Loss Coverage | OpenP…
    Ask Trek AI about this page
    ModifiedBlue Shield of CaliforniaPolicy PHP_2.04.122

    Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss

    Customize your policy alerts

    Sign up for blue_shield_of_california Policy PHP_2.04.122 alerts

    Get alerted when Policy PHP_2.04.122 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of chromosomal microarray testing of fetal or placental tissue to evaluate pregnancy loss when policy criteria are met, including qualifying second- or third-trimester intrauterine fetal death when testing may inform future pregnancies.

    Policy Summary
    PayerBlue Shield of California
    PolicyChromosomal Microarray Testing for the Evaluation of Pregnancy Loss
    Policy CodePolicy PHP_2.04.122
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDocument pre-test genetic counseling, planned post-test genetic counseling, qualifying intrauterine fetal death, and the need for testing to inform future pregnancies.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Coverage criteria for chromosomal microarray testing of fetal tissue were revised.

    The medical-necessity criteria now specify required counseling and qualifying pregnancy-loss circumstances.

    State guideline resources and DHCS materials were updated.

    The state-guideline section was revised to clarify precedence over the Policy Statement criteria.

    2Required coverage criteria
    2nd or 3rd trimesterCovered pregnancy-loss timing
    Pre- and post-testRequired genetic counseling
    2Required counseling encounters
    2State guideline resource categories
    80000–89999DHCS TAR code range

    Medical Necessity Criteria

    Chromosomal Microarray Testing for Intrauterine Fetal Death

    Chromosomal microarray testing of fetal tissue may be considered medically necessary when the following conditions apply:

    ALL of the following

    • The member has experienced intrauterine fetal death in the second or third trimester.
    • Testing of fetal cells or products of conception is needed to inform future pregnancies.
    • The member has received pre-test genetic counseling and will receive post-test genetic counseling.

    Evaluation of Pregnancy Loss

    Evaluation of pregnancy loss is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • Genetic counseling

      • The member has received pre-test genetic counseling.
      • The member will receive post-test genetic counseling.
    • Pregnancy-loss evaluation

      • The member has experienced intrauterine fetal death in the second or third trimester.
      • Testing of fetal cells or products of conception is needed to inform future pregnancies.

    Chromosomal Microarray Testing for Pregnancy Loss

    Chromosomal microarray testing of fetal tissue may be considered medically necessary for the evaluation of pregnancy loss when BOTH of the following criteria are met:

    BOTH required criteria

    • The member has received pre-test genetic counseling and will receive post-test genetic counseling.
    • The member has experienced intrauterine fetal death in the second or third trimester, and testing of fetal cells or products of conception is needed to inform future pregnancies.

    This policy does not address the use of chromosomal microarray testing for preimplantation genetic diagnosis, preimplantation genetic screening, or the evaluation of suspected chromosomal abnormalities in the postnatal period. Plans may need to alter local coverage medical policy to conform to state law regarding coverage of biomarker testing.

    Covered Pregnancy-Loss Indications

    CMA of Fetal Tissue After Second- or Third-Trimester Intrauterine Fetal Death

    For qualifying second- or third-trimester intrauterine fetal death, testing may be considered when both counseling and future-pregnancy planning requirements are met:

    Required conditions

    • Genetic counseling: The member has received pre-test genetic counseling and will receive post-test genetic counseling.

      Comprehensive counseling should address the benefits, limitations, and possible results of CMA; informed consent should include the possibility of findings of uncertain significance, nonpaternity, consanguinity, and adult-onset disease.

    • Future-pregnancy planning: The member has experienced intrauterine fetal death in the second or third trimester, and testing of fetal cells or products of conception is needed to inform future pregnancies.Second or third trimester

    Eligibility and Clinical Guidance

    For pregnancy loss at or before 20 weeks of gestation, clinical guidance identifies a maternal history of recurrent miscarriage—defined as at least two failed pregnancies—as an indication for genetic testing. For later pregnancy loss occurring after 20 weeks, genetic testing may be considered in the evaluation of intrauterine fetal death or stillbirth, with the decision made jointly by the mother or parents and the treating clinician. These guidance statements should be distinguished from the policy’s specific CMA coverage criteria, which require pre-test and post-test genetic counseling and second- or third-trimester intrauterine fetal death with testing needed to inform future pregnancies.

    Excluded Uses

    The following uses are outside the scope of this policy and are not addressed for coverage: preimplantation genetic diagnosis, preimplantation genetic screening, and evaluation of suspected chromosomal abnormalities in the postnatal period.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    TAR and Genetic Counseling Documentation

    Obtain a Treatment Authorization Request (TAR) when required for CMA and document that the member received pre-test genetic counseling and will receive post-test genetic counseling. The record must support the applicable clinical criteria and include genetic-counseling documentation when available.

    • Document pre-test and planned post-test genetic counseling.
    • Submit the applicable TAR with clinical records supporting the indication.
    Prior Authorization

    DHCS TAR and Non-Standard Benefits Requirements

    For DHCS requirements, use the applicable Provider Manual guidance for the TAR and Non-Standard Benefits List: Codes 80000 through 89999, including the Genetic Counseling and Screening and Pathology: Molecular Pathology sections. Follow the complete Provider Manual requirements when submitting the request.

    • TAR and Non-Standard Benefits List: Codes 80000 through 89999 (tar and non cd8).
    • Genetic Counseling and Screening (gene coun).

    Billing and Authorization Codes

    CPT codeCPT
    81228Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (e.g., bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis) Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities
    HCPCS codesHCPCS
    No codes listed
    DHCS TAR and Non-Standard Benefits Listmixed
    80000 thru 89999Codes 80000 thru 89999

    Clinical Background and Evidence Context

    Chromosomal microarray analysis (CMA) evaluates fetal or placental tissue from a pregnancy loss for chromosomal abnormalities, including copy-number changes and other abnormalities detectable by the testing platform. Compared with conventional karyotyping, CMA generally has a higher likelihood of producing an informative result and can identify abnormalities in specimens for which karyotyping is unsuccessful or normal. In a systematic review of stillbirth evaluations, CMA produced an informative result in approximately 90% of cases compared with 75% for conventional karyotyping; CMA also identified an additional 4% of pathogenic copy-number variants over karyotyping. Results may support reproductive decision-making and help guide evaluation of future pregnancies, although clinical yield varies with gestational age and specimen type.

    Terms and Clinical Concepts

    Fetal tissue
    Fetal tissueMay consist of fetal tissue, depending on the stage of pregnancy at the time of fetal loss.
    Formed fetusA formed fetus may qualify as fetal tissue, depending on the stage of pregnancy at the time of fetal loss.
    Placental tissuePlacental tissue derived from the fetal genotype may qualify as fetal tissue.
    Early pregnancy loss or miscarriage
    DefinitionPregnancy loss occurring at or before 20 weeks of gestational age.
    Gestational thresholdThe threshold is 20 weeks of gestational age.
    Related term
    Policy Summary
    PayerBlue Shield of California
    PolicyChromosomal Microarray Testing for the Evaluation of Pregnancy Loss
    Policy CodePolicy PHP_2.04.122
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDocument pre-test genetic counseling, planned post-test genetic counseling, qualifying intrauterine fetal death, and the need for testing to inform future pregnancies.
    SourceLink
    On This Page
    Medical Necessity CriteriaCovered Pregnancy-Loss IndicationsEligibility and Clinical GuidanceExcluded UsesAuthorization, Documentation, and Denial RisksBilling and Authorization CodesClinical Background and Evidence ContextTerms and Clinical Concepts

    Genetic Testing for Pregnancy Loss at 20 Weeks or Earlier

    Clinical guidance indicates that genetic testing may be considered for pregnancy loss at 20 weeks of gestation or earlier when all of the following apply. This guidance is not stated as an additional CMA coverage criterion in the policy coverage statement.

    Clinical guidance: The pregnancy loss occurred at 20 weeks of gestation or earlier and there is a maternal history of recurrent miscarriage.At or before 20 weeks of gestation

    Recurrent miscarriage is defined as at least two failed pregnancies.

    Genetic Testing After 20 Weeks of Gestation

    Clinical guidance indicates that genetic testing may be considered in all cases of pregnancy loss after 20 weeks of gestation. This is clinical guidance rather than an additional explicit CMA coverage criterion.

    Clinical guidance: The pregnancy loss occurred after 20 weeks of gestation.After 20 weeks of gestation

    The decision to obtain genetic testing should be made jointly by the mother or parents and the treating clinician.

    CMA for Intrauterine Fetal Demise or Stillbirth

    When further cytogenetic analysis is desired in the evaluation of intrauterine fetal demise or stillbirth:

    Clinical recommendation: Chromosomal microarray analysis is recommended for evaluation of intrauterine fetal demise or stillbirth when further cytogenetic analysis is desired.

    CMA has an increased likelihood of obtaining a result and improved detection of causative abnormalities compared with standard karyotype analysis.

    Stillbirth Evaluation

    For stillbirth evaluation, consensus guidance favors microarray when available:

    Preferred testing method: Microarray analysis should be incorporated into the stillbirth evaluation and is the preferred method.

    Compared with conventional karyotyping, microarray improves the test success rate and detection of genetic anomalies. Because of cost and logistics concerns, karyotype may be the only method readily available for some patients.

    Pregnancy-Loss Evaluation After Second- or Third-Trimester IUFD

    For evaluation of pregnancy loss after second- or third-trimester intrauterine fetal death:

    Future-pregnancy testing purpose: Testing of fetal cells or products of conception must be needed to inform future pregnancies.Second or third trimester

    Intrauterine Fetal Death in the Second or Third Trimester

    The qualifying intrauterine fetal death and testing purpose are:

    Qualifying indication: The member has experienced intrauterine fetal death in the second or third trimester, and testing of fetal cells or products of conception is needed to inform future pregnancies.Second or third trimester
  1. Pathology: Molecular Pathology (path molec).
  2. Documentation Required

    Required Clinical Documentation

    Include clinical documentation showing pre-test counseling, planned post-test counseling, an intrauterine fetal death in the second or third trimester, and that testing of fetal cells or products of conception is needed to inform future pregnancies.

    • Document counseling status before authorization.
    • Document the qualifying pregnancy-loss indication.
    • State why CMA is needed to inform future pregnancies.
    Documentation Required

    Gestational Age and Specimen Documentation

    Document gestational age and identify the specimen submitted for testing. Fetal tissue may include fetal tissue, a formed fetus, or placental tissue derived from the fetal genotype; early pregnancy loss occurs at or before 20 weeks, while intrauterine fetal demise is delivery of a non-live-born fetus after 20 weeks.

    • Record the gestational age at pregnancy loss.
    • Identify whether the specimen is fetal tissue, a formed fetus, or fetal-genotype placental tissue.
    • Support that the loss meets the applicable second- or third-trimester requirement.
    Documentation Required

    Counseling and Informed Consent

    Ensure CMA is not ordered without informed consent and comprehensive pre-test and post-test genetic counseling from an obstetrician-gynecologist or another healthcare provider with genetics expertise. Counseling must address the benefits, limitations, and possible results of CMA.

    • Discuss possible findings of uncertain significance, nonpaternity, consanguinity, and adult-onset disease.
    • Document informed consent before testing.
    • Arrange post-test counseling to explain the results.
    Documentation Required

    Clinical Review Documentation

    Submit history and physical and/or consultation notes supporting medical necessity. The record should include pregnancy history, prior treatment plans and responses, the current treatment plan, clinical justification for CMA, and genetic-counseling reports when available.

    • Document isolated or recurrent early pregnancy loss and later pregnancy loss, including intrauterine fetal demise.
    • Include previous treatment plan(s) and response(s).
    • Include the current treatment plan and clinical justification for CMA.
    • Attach genetic-counseling reports if available.
    Documentation Required

    Post-Service Records

    After service, provide the CMA of fetal tissue when applicable and the results or reports of tests performed, in addition to the pre-service clinical documentation.

    • CMA of fetal tissue, if applicable.
    • Results and reports of tests performed.

    Unsupported block type: documentation

    Denial Risk

    Indication Does Not Meet Policy Criteria

    CMA of fetal tissue is not medically necessary under this policy when the member has not experienced a qualifying intrauterine fetal death in the second or third trimester, or when testing is not needed to inform future pregnancies.

    • Early pregnancy loss at or before 20 weeks does not meet the stated intrauterine-fetal-death criterion.
    • Do not submit without documentation of the qualifying loss and testing purpose.
    Denial Risk

    Excluded Uses

    This policy does not address CMA for preimplantation genetic diagnosis or preimplantation genetic screening, or for evaluation of suspected chromosomal abnormalities in the postnatal period. Those uses are excluded from this policy’s coverage statement.

    • Preimplantation genetic diagnosis: excluded.
    • Preimplantation genetic screening: excluded.
    • Postnatal evaluation of suspected chromosomal abnormalities: excluded.
    Denial Risk

    Counseling or Laboratory Compliance Gap

    Missing required genetic counseling or use of a noncompliant laboratory-developed test creates a denial risk. Laboratory-developed tests must meet CLIA requirements, and laboratories offering them must be licensed by CLIA for high-complexity testing.

    • Use a provider with experience and expertise in genetic medicine and genetic testing methods.
    • Confirm the laboratory has the required CLIA high-complexity certification.
    • Do not proceed without required counseling documentation.
    Denial Risk

    Failure to Meet Pregnancy-Loss Medical-Necessity Criteria

    A request may be denied when pregnancy-loss medical-necessity requirements are incomplete, including missing pre-test or post-test counseling, timing that does not establish a qualifying second- or third-trimester loss, or failure to show that testing is needed to inform future pregnancies.

    • Counseling must be documented before testing and planned after testing.
    • Gestational age must support the qualifying indication.
    • The clinical purpose must be evaluation of the qualifying pregnancy loss and future-pregnancy planning.
    Denial Risk

    Failure to Meet Medical-Necessity Criteria

    Expect denial when documentation does not establish informed counseling, a qualifying intrauterine fetal death, or the medical purpose for CMA. Confirm all policy elements before ordering or submitting the claim.

    • Incomplete pre-test or post-test counseling documentation.
    • Nonqualifying pregnancy-loss circumstances.
    • No documented need to test fetal cells or products of conception to inform future pregnancies.
    Documentation Required

    Provider Actions: Complete Genetic Counseling

    Complete and document comprehensive pre-test counseling before CMA and arrange post-test counseling with an obstetrician-gynecologist or another healthcare provider who has genetics expertise. Obtain informed consent and record the counseling discussion in the clinical record.

    • Discuss benefits, limitations, possible results, and potential uncertain findings.
    • Document the counselor’s qualifications or genetics expertise.
    • Provide post-test counseling after results are available.
    Note

    Provider Actions: Shared Decision-Making and Ordering

    Use shared decision-making when considering CMA and do not order it without informed consent. Counsel the member about potential uncertain significance, nonpaternity, consanguinity, and adult-onset disease, and confirm that the testing purpose and specimen are appropriate for the policy indication.

    • Discuss the possible benefits and harms of testing.
    • Explain how results may affect the member and family.
    • Verify that the order is for an included pregnancy-loss use rather than preimplantation or postnatal testing.
    Also referred to as miscarriage.
    Intrauterine fetal demise
    DefinitionDelivery of a non-live-born fetus.
    Gestational thresholdOccurs after 20 weeks of gestational age.
    Pregnancy outcomeThe fetus is delivered without signs of life after the 20-week threshold.
    Genetic counseling
    Qualified counselorCounseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.
    PurposeHelps individuals understand the possible benefits, harms, risks, and results of genetic testing.
    Family implicationsIncludes discussion of the possible impact of genetic-testing information on the individual’s family.
    Early pregnancy loss
    DefinitionPregnancy loss occurring before 20 weeks of gestation.
    Spontaneous abortionEarly pregnancy loss may also be referred to as spontaneous abortion.
    MiscarriageEarly pregnancy loss may also be referred to as miscarriage.
    Recurrent pregnancy loss
    DefinitionTwo or more failed pregnancies.
    Recognized standardThis definition is attributed to the American Society for Reproductive Medicine.
    Clinical contextRecurrent pregnancy loss is distinct from an isolated early pregnancy loss.
    Intrauterine fetal demise
    DefinitionFetal loss occurring after 20 weeks of gestation.
    StillbirthIntrauterine fetal demise may also be referred to as stillbirth.
    Intrauterine fetal deathIntrauterine fetal demise may also be referred to as intrauterine fetal death.
    Chromosomal microarray
    Test typeA genomic microarray test.
    Primary detectionDetects copy-number variants.
    Additional findingsDepending on the platform, may detect runs of homozygosity, triploidy, or uniparental disomy.
    Array comparative genomic hybridization
    MethodCompares a reference genomic sequence with the patient, or unknown, sequence.
    Detected abnormalitiesDetects copy-number variants, including deletions and duplications.
    TechnologyUses a microarray containing cloned or synthesized DNA fragments with known sequences.
    Single-nucleotide variant microarray
    MethodUses a microarray containing known single-nucleotide variants.
    Reference sequenceDoes not use a separate reference genomic sequence; only the unknown sample is hybridized to the array platform.
    Evaluation methodEvaluates the presence or absence of known sequence variants by signal intensity to provide information about copy numbers.
    Clinically useful
    DefinitionA test is clinically useful when its results inform management decisions that improve the net health outcome of care.
    Effective treatmentClinical usefulness may include enabling patients to receive correct or more effective therapy.
    Avoiding unnecessary careClinical usefulness may include avoiding unnecessary therapy or testing.
    Direct evidence
    Evidence basisDirect clinical-utility evidence comes from studies comparing health outcomes for patients managed with and without the test.
    Preferred designBecause these are intervention studies, randomized controlled trials are preferred.
    Outcome focusThe comparison evaluates whether use of the test changes patient health outcomes.
    Clinically useful
    Core definitionA test is clinically useful when its results inform management decisions that improve the net health outcome.
    Treatment exampleExamples include enabling correct or more effective therapy.
    Testing exampleAnother example is avoiding unnecessary therapy or testing.
    Chain of evidence
    Evidence typeA chain of evidence is an indirect approach to evaluating clinical utility.
    FoundationIndirect evidence on clinical utility rests on clinical validity.
    LimitationIf evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.
    Chromosomal microarray analysis (CMA)
    MethodMeasures gains and losses of DNA throughout the human genome.
    Chromosomal findingsIdentifies chromosomal aneuploidy and large structural changes that may otherwise be identified by standard karyotype analysis.
    Submicroscopic findingsIdentifies abnormalities too small to be detected by traditional modalities.
    Recurrent pregnancy loss
    DefinitionRecurrent pregnancy loss evaluation may proceed after two consecutive clinical pregnancy losses.
    Required sequenceThe losses must be consecutive clinical pregnancy losses.
    Evaluation contextThe definition applies to evaluation of recurrent pregnancy loss.
    IUFD
    MeaningIUFD means intrauterine fetal demise.
    Pregnancy timingIt is described in the documentation requirements as later pregnancy loss.
    Documentation contextClinical records should identify later pregnancy loss, including intrauterine fetal demise, when applicable.
    Chromosomal microarray analysis (CMA)
    Assay typeCytogenomic constitutional genome-wide microarray analysis.
    Genomic targetsInterrogates genomic regions for copy-number variants and/or single-nucleotide polymorphism variants.
    Clinical purposeAnalyzes chromosomal abnormalities, including through genome-wide copy-number and SNP variant assessment.